Search

Search Results

• P100 | ATOGEPANT DEMONSTRATES GREATER IMPROVEMENT IN FUNCTION USING THE ACTIVITY IMPAIRMENT IN MIGRAINE-DIARY (AIM-D) DURING INTERICTAL DAYS: POST-HOC ANALYSIS FROM THE PROGRESS CHRONIC MIGRAINE TRIAL

  R. Masselli¹, R. B. Lipton², P. Gandhi³, A. Maassen van den Brink⁴, E. Leroux⁵, R. Halker Singh⁶, M. Duan³, B. Dabruzzo³, K. Umashankar³, J. Stokes³, D. C. Buse⁷ | ¹AbbVie Srl, Rome, Italy; ²Department of Neurology, General Hospital Sint-Jan Bruges, Belgium; ³AbbVie Inc. North Chicago, IL, USA; ⁴Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Italy; ⁵Headache Unit, Neurology Department, Vall d'Hebron University Hospital, Barcelona, Spain; Headache and Neurological Pain Research; ⁶Headache and Neurological Pain Research Group, Vall d'Hebron Institute of Research, Universitat Autonoma de Barcelona, Spain; ⁷University Hospital Bonn, Germany; ⁸Charité Universitätsmedizin Berlin, Germany; ⁹Neurology Department, Hospital da Luz, Lisboa, Portugal; ¹⁰Center for Interdisciplinary Research in Health, Universidade Católica Portuguesa, Lisboa, Portugal

  03-11-2026

  DOI https://doi.org/10.4081/cc.2026.16056

  • 0 abstract views
  • 0 PDF